Arcus Biosciences Inc (RCUS)
15.30
-0.26
(-1.67%)
USD |
NYSE |
Nov 05, 16:00
15.30
0.00 (0.00%)
After-Hours: 20:00
Arcus Biosciences Research and Development Expense (Annual): 340.00M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 340.00M |
| December 31, 2022 | 288.00M |
| December 31, 2021 | 257.00M |
| December 31, 2020 | 159.00M |
| Date | Value |
|---|---|
| December 31, 2019 | 78.48M |
| December 31, 2018 | 49.65M |
| December 31, 2017 | 47.22M |
| December 31, 2016 | 14.25M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
78.48M
Minimum
2019
340.00M
Maximum
2023
224.50M
Average
257.00M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Merck & Co Inc | 30.53B |
| Intra-Cellular Therapies Inc | 180.14M |
| Syndax Pharmaceuticals Inc | 163.03M |
| Clearside Biomedical Inc | 20.85M |
| Janux Therapeutics Inc | 54.92M |